



NORDIC CONGRESS

29-30 AUGUST 2018 | NASDAQ OFFICES | STOCKHOLM



1
CEO FORUM

50+
INVESTORS

18
SHOWCASES

150
ATTENDEES

SEK

NOK

DDK

€

\$

LIFE SCIENCE EXECUTIVES'
LEADERSHIP AND INVESTMENT CONGRESS

HOST PARTNER



GOLD PARTNERS



VINGE



SILVER PARTNER

TheBlueshirtGroup

PRODUCED BY:



CONNECTING NORDIC LIFE SCIENCE EXECUTIVE LEADERS... THE LSX NORDIC CONGRESS IN 2018!

The LSX Nordic Congress is a high-calibre, senior executive conference and partnering event providing the education, strategies, solutions, and contacts that life science companies need to enable more effective investment, business planning and partnering within their businesses.

The Nordic region has long produced world-leading science and innovation and Nasdaq Nordic is one of the leading hubs for biotech companies in Europe, strengthened further by a hugely active IPO market over the last two years. However, growth and venture funding is lacking compared with other hubs and listed Nordic companies face a number of specific challenges in their ongoing funding, growth, development and internationalisation.

With our relentless focus on quality peer-to-peer discussion, high-level networking and partnering, unique formats and a vetted, high-calibre audience, we will bring together the people that matter to the future of life sciences in the Nordic region to address these challenges and work towards actionable outcomes to help it flourish.

6 REASONS TO ATTEND...

X UNDERSTAND... the latest trends, forecasts and insights from leading regional investment funds and life science CxOs

X NETWORK... with 150 Nordic life science CxOs, investors and key partners, convening to address key executive issues facing companies in the region

X HEAR... war stories, advice and key success factors from CEOs who have taken their company through major milestones in their businesses

X PRESENT... your company to an audience of qualified investors in person, as well as being webcast and recorded in the Inv€\$table showcase sessions

X PARTICIPATE... in our unique invitation-only Chatham House Rule CEO Forum, exclusively for listed company CEOs and CFOs

X CONNECT WITH PURPOSE... to our community - the life science executives of LSX.



AGENDA AT A GLANCE

Wednesday 29 August



Thursday 30 August

Capital markets outlook: will the Nordic listing boom continue?

Building a thriving world class life science hub in the Nordics

Nurturing a more vibrant growth and venture capital investment environment

NETWORKING BREAK

Institutional weight behind maturing life science companies

Alternative investment and financing sources



NETWORKING LUNCH

Strategic Partnerships: Building internationally competitive businesses

Pharma's role in developing the Nordic ecosystem



NETWORKING BREAK

Anatomy of a Nordic IPO

Building for the future: board development and retaining, attracting and integrating talent



DRINKS RECEPTION

AGENDA - Thursday 30 August

9.00

WELCOME REMARKS

Josh Dance, SVP, Biotech and Money

9.10

CAPITAL MARKETS OUTLOOK

Adam Kostyal, SVP Listing Services - Europe, Nasdaq

9.30

OPENING KEYNOTE PANEL: BUILDING A THRIVING WORLD CLASS LIFE SCIENCE HUB IN THE NORDICS

Government and industry leaders discuss which policy and industry initiatives could help build upon the region's long history of life science leadership and innovation, and work towards an even more internationally competitive life science and healthcare hub and the growth of \$billion businesses.

- How are government and agency bodies working to improve policy and conditions for life science companies?
- Could R&D tax credits and other business incentives for corporates and investors help retain talent and nurture a more robust and internationally attractive life science and healthcare ecosystem?
- Could a more productive environment with increased incentives for patients to participate in research be developed?

Thomas Lönngren, Former Head of the EMA and Strategic Advisor, NDA Group (moderator)

Jenni Nordborg, National Coordinator Life Sciences, Government Offices of Sweden
Rasmus Beedholm-Ebsen, Senior Advisor - Life Sciences, Invest in Denmark, Ministry of Foreign Affairs of Denmark

Viktor Drvota, CEO, Karolinska Development

Farzad Abdi-Dezfuli, Partner, Investment Advisor, Sarsia Seed

Jonas Hansson, former CEO, Wilson Therapeutics

10.15

KEYNOTE PANEL: NURTURING A MORE VIBRANT GROWTH AND VENTURE CAPITAL INVESTMENT ENVIRONMENT

Venture fund executives have a frank and open discussion and debate on the relative dearth of private growth and venture capital, debate strategies for nurturing and funding innovation, and examine appetite for future growth and follow-on investment in Nordic life science companies.

- What strategies are in place to nurture the venture and growth ecosystem?
- Could the boom in public listings of life sciences companies attract more global venture capital investment to the region?
- Reaching international specialists funding: syndication and developing networks to access UK, European and US growth capital

Terry O'Dwyer, co-CEO, LSX (moderator)

Søren Møller, Managing Partner, Novo Seeds

Mårten Steen, Partner, HealthCap

Sten Verland, Senior Partner, Sunstone Life Science Ventures

Ingrid Teigland Akay, Managing Partner, Hadean Ventures

Nina Rawal, Head of Life Science, Industrifonden

11.00

NETWORKING BREAK

11.30

INSTITUTIONAL WEIGHT BEHIND MATURING COMPANIES

Fund managers have an open discussion on their views on the life science and healthcare sectors and their appetite for investment in the Nordic region's maturing public corporates.

- Do institutional investors look beyond regional main markets to the growth markets?
- Could growth markets be better promoted or made more attractive?
- Institutional views on the Nordic healthcare sector in a global context

Jonas Söderström, CEO & Editor, BioStock (moderator)

Ulrica Slåne Bjerke, Founder and CIO, Arctic Aurora Life Sciences

Åsa Riisberg, Partner, EQT Partners

Ragnar Hellenius, Partner, PAI Partners

Mattias Häggblom, Portfolio Manager - Global Healthcare, Swedbank Robur

12.15

ALTERNATIVE INVESTMENT AND FINANCING SOURCES

Investors, bankers and executives discuss new, alternative and innovative capital sources capital which are increasingly playing a role in the European investment landscape.

- Are emerging markets funds a new route for growth capital?
- Which banks and institutions are open to innovative financing and funding models? When should debt financing and bridge loans be considered?
- Can a new wave of later stage and crossover funds bring later stage capital for growth?
- What other innovative financing and business models can be adopted?

Adam Bruce, Founder and Executive Board, TikoMed (moderator)

Aris Constantinidis, General Partner, Kreos Capital

Sascha Berger, Principal, TVM Capital

Aditya Puri, Partner, Investments, Xeraya Capital



CEOs present to investors in person and via webcast, with their presentation recorded for our exclusive investor portal. Six companies present for 15 minutes including Q&A.

11.30 Anders Månsson
CEO



11.45 Pekka Mattila
CEO



12.00 Henrik Rammer
Chairman



12.15 Jan Fjellström
Managing Director



12.30 Per-Olof Schrewelius
CFO



12.30 Sten Sörensen
CEO



13.00

NETWORKING LUNCH

14.00

STRATEGIC PARTNERSHIPS: BUILDING INTERNATIONALLY COMPETITIVE BUSINESSES

Executives and leading expert advisers and partners debate the key success factors for local and international partnerships.

- What are the key considerations for CxOs building their companies to be internationally competitive?
- Which cross-border collaboration strategies, and which advisers, are vital for success?
- Developing the right strategic partnerships for cost effective and punctual clinical trials
- Controlling your own destiny; delivering true shareholder value by developing as long as possible to be able to hold out for higher returns

Don deBethizy, Chairman, Saniona (moderator)

Christine Lind, CEO, Medivir

Mats Blom, CFO, Zealand Pharma

Nikolaj Sørensen, CEO, Orexo



14.00 Christian Jørgensen
CEO



14.15 Erik Kinnman
CEO



14.30 Peter Buhl Jensen
CEO



14.45

PHARMA'S ROLE IN DEVELOPING THE NORDIC ECOSYSTEM

Regional and active pharma leaders discuss and debate the evolving role of pharma in early stage collaborations and partnership opportunities.

- How are local and international pharma supporting the Nordic life science ecosystem?
- What support is available from regional pharma companies for innovative life science companies?
- Which areas of innovation are pharma focussed on?
- How can companies best position themselves for effective partnership and collaboration?

Terry O'Dwyer, co-CEO, LSX (moderator)

Miriam Frieden, Vice President R&D Innovation Sourcing, Novo Nordisk

Anders Holmén, VP Pharmaceutical Sciences, AstraZeneca

Nathalie ter Wengel, European Head Global External R&D and Innovation, Pfizer

Khatereh Ahmadi, Executive Director, Oncology Search and Evaluation Lead, MSD



14.45 Jan Allenfall
CEO



15.00 Nikolaj Sørensen
CEO



15.15 Claus Bo Svendsen
CEO



15.30

NETWORKING LUNCH

16.00

ANATOMY OF A NORDIC IPO

Executives from leading life science companies that have recently listed on Nordic markets share the key success factors and how they've prepared and restructured their business for life on public markets.

- How are successful public listings being planned and structured?
- When is right to list? What are the key considerations companies should make before considering listing?
- What do the licensing and collaboration transactions that underpin these IPOs look like?
- How can companies with a successful listing and strong owners take the next step?

Adam Kostyal, SVP Listing Services - Europe, Nasdaq (moderator)

Ole Thastrup, CEO, 2cureX

Per Andersson, CEO, Xspray Pharma

Christer Ahlberg, CEO, Sedana Medical



16.00 Lars-Erik Eriksson
CEO



16.15 Christine Lind
CEO



16.30 Cecilia Edström
CFO



16.45 Jamal El-Moseh
CEO



17.00 Pekka Simula
CEO



17.15 Thomas Feldthus
CFO



16.45

BUILDING FOR THE FUTURE: BOARD DEVELOPMENT AND RETAINING, ATTRACTING AND INTEGRATING TALENT

Executives discuss the depth and breadth of talent in the Nordics, and the critical importance of building diverse boards, with the right skill set.

- Does more need to be done to protect against talent being attracted away to higher-paying countries in Europe and the US?
- Can international talent be more effectively attracted to the region?
- How to build and develop the company's early team to have the diversity of backgrounds, experience and perspectives for later success

Adam Bruce, Executive Board, TikoMed (moderator)

Julie Silber, Managing Partner, The Blueshirt Group

Jenni Nordborg, Director, National Coordinator Life Sciences, Government Offices of Sweden

Don deBethizy, Chairman, Saniona

17.30

NETWORKING DRINKS

AGENDA - Wednesday 29 August

09.00



Teaming up with some of the world's foremost experts, advisers, bankers and consultants, the IPO bootcamp is designed to help CEOs and CFOs of private life science companies navigate the how, what, where and when of a successful IPO.

The bootcamp has been attended by 40 pre-IPO companies over the last 18 months who are considering listing in Europe and the US.

13.00

The Nordic IPO bootcamp is an invitation only one-day workshop, conference and series of 1-2-1 meetings. The bootcamp provides CEOs and CFOs contemplating an IPO with a unique opportunity to come together for a series of frank and open discussions and case studies with peers and executives who have recently been through the process. Participants will also have access to for tailored and bespoke 1-2-1 advice with some of the world's foremost experts, advisers, bankers and consultants.

Co-hosts:



TheBlueshirtGroup



LSX' unique CEO Forums provides a unique, powerful and valuable space for the candid sharing of experience between the sector's most senior executives so that they can leave with new ideas that will drive their businesses and the sector forward.

The Nordic CEO Forum is an invitation only roundtable forum where all participants are active discussants and have an equal voice. The forum is exclusively for listed company CxOs, to ensure conversation is meaningful and tailored, and follows a strict Chatham House Rule policy. The forum includes case study peer review and a general discussion focused on brainstorming solutions to the collective challenges of CxOs in the sector.

Co-hosts:



18.00



The LSX Investor Club is for active and engaged members of the LSX investor community and has been designed to help investors connect and network with their peers, find syndication partners, benchmark, share ideas, resources, tools and war stories and access unique investment opportunities and deal flow, as well as promote their funds and portfolio companies through our various media channels.

The Investor Club Dinner is open to members (discounted) and non-members and is one of the investor-only peer-to-peer dinners and socials which form part of the Club Calendar.



The CEO Dinner closes off the day of the CEO Forum and is an opportunity for executives of the region's listed companies to continue discussions in a more informal setting over an exclusive dinner hosted by LSX.

The dinner will be held at a restaurant in Stockholm away from the event venue.

It is open to all CEO forum participants and included as part of the registration for the day, leading into the LSX Nordic Congress on the following day.


INVESTORS AND PHARMA ATTENDING THE LSX NORDIC CONGRESS



Biolinka Investment Holding



IPF Partners



As well as local and international VCs, CVC, private equity and asset management firms and institutional investors above, LSX Nordic Congress will also convene a selection of family office and high quality and profile retail investors who invest in life science companies on the public markets, brought in partnership with BioStock.

SPEAKER AND AGENDA ENQUIRIES

Josh Dance, SVP
josh@biotechandmoney.com
+44 (0) 203 637 5908

INVESTOR ENQUIRIES

Emily Vipond, Head of Investor Relations
emily@biotechandmoney.com
+44 (0) 203 637 5908

PARTNERSHIP ENQUIRIES

Matt Pullan, SVP Business Development
matt@biotechandmoney.com
+44 (0) 203 637 5908

DELEGATE ENQUIRIES

Elis Jansen, Business Development Manager
tom@biotechandmoney.com
+44 (0) 203 637 5908

www.biotechandmoney.com/lxx-nordic-congress



NORDIC CONGRESS

PRODUCED BY:

biotechandmoney
bringing deals to life



CONNECT WITH PURPOSE

PARTNERSHIP ENQUIRIES

Matt Pullan, SVP
matt@biotechandmoney.com
+44 (0) 203 637 5908

SPEAKER AND AGENDA ENQUIRIES

Josh Dance, SVP
josh@biotechandmoney.com
+44 (0) 203 637 5908

MEDIA PARTNERS



OSLO CANCER
CLUSTER



The network
for **life science**
executive leaders

THE NEW NAME FOR

biotechandmoney
bringing deals to life